Harshini Neelakantan
Company: Ridgeline Therapeutics
Job title: Executive Director, Research & Development
Seminars:
Correcting Dysregulated Fat Metabolism: Unraveling a Novel Approach to Reverse Obesity, NASH & Type 2 Diabetes 12:00 pm
Leveraging an oral small molecule therapeutic to sustainably modulate adipose tissue metabolism Targeting the root cause: preventing or reversing fatty liver disease and the progression to NASH Obesity, NASH, and T2D: interrogating animal studies and translation to the clinicRead more
day: Day 1 Stream 1 AM